Literature DB >> 25481776

Serum visfatin and omentin levels in slow coronary flow.

Taner Ucgun1, Cengiz Başar2, Ramazan Memişoğulları1, Hilmi Demirin1, Yasin Türker3, Yusuf Aslantaş3.   

Abstract

OBJECTIVE: The adipocytokines visfatin and omentin have a direct effect on inflammation and endothelial injury. The expression of visfatin is closely associated with the expression of proinflammatory cytokines. Omentin has an anti-inflammatory effect and is inversely associated with coronary artery disease (CAD). The slow coronary flow phenomenon is an angiographic finding characterized by delayed distal vessel opacification in the absence of significant epicardial coronary disease. The pathophysiology of SCF has not been clearly identified, although multiple abnormalities including endothelial dysfunction, atherothrombosis and inflammation have been reported. However, the relationship between visfatin, omentin and SCF is still unknown. In this study, we aimed to investigate the relationship of these adipocytokines with SCF.
METHODS: The study included slow coronary flow (n=45) and normal coronary flow (n=55) subjects, according to the corrected TIMI frame count, who underwent angiography in the catheterization laboratory of Duzce University. Statistical analyses were performed with SPSS version 12.
RESULTS: Visfatin levels were significantly higher in patients with SCF than in controls (p<0.001). Plasma omentin levels were lower in the SCF group than in controls, although without statistical significance. Visfatin, gender and platelet count were significant predictors of SCF in multivariate logistic regression analysis (OR 0.748, 95% CI 0.632-0.886, p=0.01; OR 30.016, 95% CI 4.355-206.8, p=0.01; OR1.028, 95% CI 1.006-1.050, p=0.011, respectively).
CONCLUSION: Adipocytokines such as visfatin and omentin may play a role in the pathogenesis of coronary slow flow.
Copyright © 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved.

Entities:  

Keywords:  Fluxo coronário lento; Omentin; Slow coronary flow; Visfatin; Visfatina

Mesh:

Substances:

Year:  2014        PMID: 25481776     DOI: 10.1016/j.repc.2014.04.007

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  4 in total

1.  Relationship between serum visfatin levels and coronary slow-flow phenomenon.

Authors:  Huseyin Altug Cakmak; Serkan Aslan; Ahmet Arif Yalcin; Ibrahim Faruk Akturk; Burce Yalcin; Fatih Uzun; Derya Ozturk; Mehmet Erturk; Mehmet Gul
Journal:  Herz       Date:  2015-05-05       Impact factor: 1.443

2.  Degradation of proinsulin C-peptide in kidney and placenta extracts by a specific endoprotease activity.

Authors:  E Melles; H Jörnvall; S Tryggvason; K Gemzell Danielsson; K Ekberg; K Tryggvason; J Wahren; T Bergman
Journal:  Cell Mol Life Sci       Date:  2004-12       Impact factor: 9.261

3.  Elevated levels of sIL-2R, TNF-α and hs-CRP are independent risk factors for post percutaneous coronary intervention coronary slow flow in patients with non-ST segment elevation acute coronary syndrome.

Authors:  Cheng Wang; Yan Wu; Yang Su; Bin Mao; Yihong Luo; Yexiang Yan; Kun Hu; Yi Lu; Wenliang Che; Minying Wan
Journal:  Int J Cardiovasc Imaging       Date:  2022-02-19       Impact factor: 2.357

4.  Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.

Authors:  Hakan Duman; Ali Gökhan Özyıldız; İlkay Bahçeci; Handan Duman; Abdulkadir Uslu; Elif Ergül
Journal:  Ther Adv Cardiovasc Dis       Date:  2019 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.